Literature DB >> 19400494

Outcome of patients receiving high dose vasopressor therapy: a retrospective cohort study.

C R Jenkins1, C D Gomersall, P Leung, G M Joynt.   

Abstract

The aim of this study was to determine the hospital survival of patients receiving high doses of catecholamines. A retrospective observational study was conducted in a 22-bed multidisciplinary adult intensive care unit of a tertiary referral university hospital. All patients (n = 64) receiving > 100 microg/min of adrenaline or noradrenaline or adrenaline and noradrenaline combined over a one-year period were studied to determine survival to intensive care unit and hospital discharge. Four patients survived to intensive care unit discharge and hospital discharge (6.25%, 95% CI 0.3 to 12.2%). Survival was 3.3% (95% CI 0 to 7.9%) in the subgroup of 60 patients who received > 100 microg/min noradrenaline and 3.6% (95% CI 0 to 8.6%) in the 55 patients who received > 2 microg/kg/min noradrenaline. None of the 32 patients who received > 200 microg/min noradrenaline survived. We conclude that the survival of patients requiring high doses of catecholamines is poor but the use of such doses is probably not futile. It remains for individual clinicians, patients and their surrogates to decide whether use of high doses of vasopressor is appropriate, given the low probability of survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19400494     DOI: 10.1177/0310057X0903700212

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  11 in total

1.  Survival after shock requiring high-dose vasopressor therapy.

Authors:  Samuel M Brown; Michael J Lanspa; Jason P Jones; Kathryn G Kuttler; Yao Li; Rick Carlson; Russell R Miller; Eliotte L Hirshberg; Colin K Grissom; Alan H Morris
Journal:  Chest       Date:  2013-03       Impact factor: 9.410

2.  Catecholamine dosing and survival in adult intensive care unit patients.

Authors:  Marc Kastrup; Jan Braun; Magnus Kaffarnik; Vera von Dossow-Hanfstingl; Robert Ahlborn; Klaus-D Wernecke; Claudia Spies
Journal:  World J Surg       Date:  2013-04       Impact factor: 3.352

Review 3.  Vasopressor Choice and Timing in Vasodilatory Shock.

Authors:  Patrick M Wieruszewski; Ashish K Khanna
Journal:  Crit Care       Date:  2022-03-22       Impact factor: 9.097

Review 4.  Therapeutic strategies for high-dose vasopressor-dependent shock.

Authors:  Estevão Bassi; Marcelo Park; Luciano Cesar Pontes Azevedo
Journal:  Crit Care Res Pract       Date:  2013-09-15

5.  Outcome of patients with septic shock and high-dose vasopressor therapy.

Authors:  Thomas Auchet; Marie-Alix Regnier; Nicolas Girerd; Bruno Levy
Journal:  Ann Intensive Care       Date:  2017-04-20       Impact factor: 6.925

6.  Comparison of first-line and second-line terlipressin versus sole norepinephrine in fulminant ovine septic shock.

Authors:  Tim G Kampmeier; Philip H Arnemann; Michael Hessler; Laura M Seidel; Karsten Becker; Andrea Morelli; Sebastian W Rehberg; Christian Ertmer
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

7.  Timing of administration of epinephrine predicts the responsiveness to epinephrine in norepinephrine-refractory septic shock: a retrospective study.

Authors:  Daisuke Kasugai; Mitsuaki Nishikimi; Kazuki Nishida; Michiko Higashi; Takanori Yamamoto; Atsushi Numaguchi; Kunihiko Takahashi; Shigeyuki Matsui; Naoyuki Matsuda
Journal:  J Intensive Care       Date:  2019-04-05

8.  Methylene blue administration in patients with refractory distributive shock - a retrospective study.

Authors:  Michal Porizka; Petr Kopecky; Helena Dvorakova; Jan Kunstyr; Michal Lips; Pavel Michalek; Martin Balik
Journal:  Sci Rep       Date:  2020-02-04       Impact factor: 4.379

9.  Venoarterial extracorporeal membrane oxygenation as mechanical circulatory support in adult septic shock: a systematic review and meta-analysis with individual participant data meta-regression analysis.

Authors:  Ryan Ruiyang Ling; Kollengode Ramanathan; Wynne Hsing Poon; Chuen Seng Tan; Nicolas Brechot; Daniel Brodie; Alain Combes; Graeme MacLaren
Journal:  Crit Care       Date:  2021-07-14       Impact factor: 9.097

Review 10.  Angiotensin II: a new therapeutic option for vasodilatory shock.

Authors:  Rachel L Bussard; Laurence W Busse
Journal:  Ther Clin Risk Manag       Date:  2018-07-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.